MCID: CNN002
MIFTS: 40

Cannabis Abuse

Categories: Mental diseases

Aliases & Classifications for Cannabis Abuse

Summaries for Cannabis Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of cannabis despite negative consequences.

MalaCards based summary : Cannabis Abuse, also known as marijuana abuse, is related to cannabis dependence and schizophrenia. An important gene associated with Cannabis Abuse is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are Ras signaling pathway and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and brain, and related phenotype is integument.

Related Diseases for Cannabis Abuse

Diseases related to Cannabis Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
# Related Disease Score Top Affiliating Genes
1 cannabis dependence 11.9
2 schizophrenia 10.4
3 neuropathy, hereditary sensory and autonomic, type v 10.1 BDNF NGF
4 adult astrocytic tumour 10.1 BDNF NGF
5 paine syndrome 10.1 BDNF NGF
6 ocular dominance 10.1 BDNF NGF
7 interstitial cystitis 10.1 BDNF NGF
8 autonomic nervous system neoplasm 10.1 BDNF NGF
9 peripheral nervous system neoplasm 10.1 BDNF NGF
10 tendinosis 10.1 BDNF CNR1
11 amnestic disorder 10.1 BDNF CNR1
12 toxic encephalopathy 10.1 BDNF NGF
13 diabetic neuropathy 10.0 CNR1 NGF
14 post-traumatic stress disorder 10.0 BDNF CNR1
15 eating disorder 10.0 BDNF CNR1
16 alcohol abuse 10.0 BDNF CNR1
17 specific developmental disorder 9.9 BDNF CNR1
18 substance dependence 9.9 BDNF CNR1
19 central nervous system disease 9.9 BDNF CNR1 NGF
20 myocardial infarction 9.9
21 membranous nephropathy 9.9
22 acute myocardial infarction 9.9
23 glomerulonephritis 9.9
24 atrial fibrillation 9.9
25 epilepsy 9.9
26 human immunodeficiency virus infectious disease 9.9
27 cerebrovascular disease 9.9
28 depression 9.9
29 parkinson disease, late-onset 9.9 BDNF CNR1 NGF
30 chiari malformation type i 9.9
31 chiari malformation type ii 9.9
32 anxiety 9.9
33 alexithymia 9.9
34 depersonalization disorder 9.9
35 substance abuse 9.9
36 myelitis 9.9
37 cocaine dependence 9.9
38 chiari malformation 9.9
39 transverse myelitis 9.9
40 amyotrophic lateral sclerosis 1 9.8 BDNF CNR1 NGF
41 disease of mental health 9.8 BDNF CNR1
42 drug dependence 9.8 BDNF CHRNB3 CNR1
43 multiple sclerosis 9.8 BDNF CNR1 CNR2 NGF

Graphical network of the top 20 diseases related to Cannabis Abuse:



Diseases related to Cannabis Abuse

Symptoms & Phenotypes for Cannabis Abuse

MGI Mouse Phenotypes related to Cannabis Abuse:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.02 BDNF CNR1 CNR2 NGF SLC17A8

Drugs & Therapeutics for Cannabis Abuse

Drugs for Cannabis Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
3
Clozapine Approved Phase 4,Not Applicable 5786-21-0 2818
4 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
5 Serotonin Antagonists Phase 4,Not Applicable
6 Serotonin Agents Phase 4,Phase 2,Not Applicable
7 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Dopamine Antagonists Phase 4,Not Applicable
9 GABA Agents Phase 4,Phase 3,Not Applicable
10 Dopamine Agents Phase 4,Not Applicable
11 Tranquilizing Agents Phase 4,Phase 3,Not Applicable
12 Antipsychotic Agents Phase 4,Phase 3,Not Applicable
13 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
15 Adrenergic Agents Phase 4,Phase 2,Phase 3
16 Atomoxetine Hydrochloride Phase 4,Phase 2
17
Serotonin Investigational, Nutraceutical Phase 4,Phase 2,Not Applicable 50-67-9 5202
18
Ethanol Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 64-17-5 702
19
Lithium carbonate Approved Phase 3 554-13-2
20
Valproic Acid Approved, Investigational Phase 3 99-66-1 3121
21
Dronabinol Approved, Illicit Phase 2, Phase 3,Phase 1,Early Phase 1 1972-08-3 16078
22
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
23 Anti-Infective Agents Phase 2, Phase 3,Phase 1,Not Applicable
24 Anti-Infective Agents, Local Phase 2, Phase 3,Phase 1,Not Applicable
25 Anticonvulsants Phase 3,Phase 2
26 Antidepressive Agents Phase 3,Phase 2
27 Antimanic Agents Phase 3
28 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 1,Early Phase 1
29 Hallucinogens Phase 2, Phase 3,Early Phase 1
30 Hormone Antagonists Phase 2, Phase 3,Early Phase 1
31 Analgesics Phase 2, Phase 3,Phase 1,Early Phase 1
32 Cannabinoid Receptor Agonists Phase 2, Phase 3,Early Phase 1
33 Autonomic Agents Phase 2, Phase 3,Phase 1
34 Hormones Phase 2, Phase 3,Early Phase 1
35 Analgesics, Non-Narcotic Phase 2, Phase 3,Phase 1,Early Phase 1
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3,Early Phase 1
37 Quetiapine Fumarate Phase 3 111974-72-2
38 Sympatholytics Phase 2, Phase 3
39 Adrenergic alpha-Agonists Phase 2, Phase 3
40 Adrenergic Agonists Phase 2, Phase 3
41 Antihypertensive Agents Phase 2, Phase 3
42 Adrenergic alpha-2 Receptor Agonists Phase 2, Phase 3
43
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
44
Topiramate Approved Phase 2 97240-79-4 5284627
45
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
46 Antidotes Phase 2
47 Expectorants Phase 2
48 Antioxidants Phase 2
49 N-monoacetylcystine Phase 2
50 Respiratory System Agents Phase 2

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 Clozapine for Cannabis Use in Schizophrenia Completed NCT01639872 Phase 4 Clozapine;Risperidone
2 Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Completed NCT00498550 Phase 4 Clozapine;Treatment as usual
3 Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE Terminated NCT00687609 Phase 4 Atomoxetine
4 A Comparison of Adolescent Group Therapy and Transitional Family Therapy for Adolescent Alcohol and Drug Abusers Unknown status NCT00484367 Phase 2, Phase 3
5 Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder Completed NCT00194129 Phase 3 Lithium;Divalproex;Placebo
6 Quetiapine XR in Schizophrenic Patients Terminated NCT01071135 Phase 3 Quetiapine XR
7 Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Terminated NCT01598896 Phase 2, Phase 3 Dronabinol;Clonidine;Placebo
8 Integration of (iSBIRT) for Teen Drug Use Into a Pediatric Network Withdrawn NCT01454206 Phase 2, Phase 3
9 Clinical Trial of N-acetylcysteine Versus Placebo Efficacy in the Cannabis Withdrawal Unknown status NCT01439828 Phase 2 N-acetylcystein
10 Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents Completed NCT01110434 Phase 2 Topiramate;Placebo
11 The Teen Marijuana Check-Up Completed NCT00350285 Phase 2
12 Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence Completed NCT00149643 Phase 2 Fluoxetine
13 Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder Completed NCT00142961 Phase 2 Atomoxetine
14 Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects Not yet recruiting NCT03717272 Phase 2 AEF0117;Placebo oral capsule
15 Dose-response of Cannabis and Driving Not yet recruiting NCT03656029 Phase 2 Cannabis;Placebo
16 Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders Completed NCT01875796 Phase 1
17 Relapse Prevention for Suicidal Dually Diagnosed Youths Completed NCT00589641 Phase 1
18 Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment Completed NCT00783185 Phase 1
19 Effects of Sativex(Registered Trademark) and Oral THC on Attention, Affect, Working Memory, Reversal Learning, Physiology and Brain Activation Completed NCT01037608 Phase 1 Sativex(Registered Trademark);THC
20 Medications Development for the Treatment of Cannabis Related Disorders Completed NCT01204723 Phase 1 Placebo Aprepitant;Active Aprepitant
21 Trial of Computerized SBI to Reduce Teen Alcohol Use Withdrawn NCT01784627 Phase 1
22 INCA - Intervention and Neuropsychology in Cannabis Abuse Unknown status NCT00279604 Not Applicable
23 Electrophysiological Study of the Functioning of Magnocellular Visual Pathway in Regular Cannabis Users Unknown status NCT02864680 Not Applicable
24 Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis Completed NCT00484302 Not Applicable
25 Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse Completed NCT00798109 Not Applicable
26 Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms Completed NCT01603992
27 Niacin Flushing as Marker of Cannabis Effects on Arachidonic Acid Pathways in Schizophrenia Completed NCT00376233
28 Study Comparing Two Types of Psychotherapy for Treating Depression and Substance Abuse Completed NCT00108407 Not Applicable
29 First Episode Schizophrenia and Cannabis-Related Disorder Study Completed NCT00573287 Not Applicable clozapine;risperidone
30 Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer Completed NCT01647425
31 Dronabinol Interactions With Cognitive Enhancing Drug in Humans Completed NCT00842985 Early Phase 1 drug condition
32 Treatment for Teens With Alcohol Abuse and Depression Recruiting NCT02227589 Not Applicable
33 Affective Management Training for Cannabis Misuse Recruiting NCT03432013 Not Applicable
34 Suicide Re Attempts in Young Adults After First Suicide Attempt : Socio-demographic, Clinical and Biological Correlates Recruiting NCT03538197 Not Applicable
35 COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE Active, not recruiting NCT02319746 Not Applicable
36 Alcohol and Tobacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support Withdrawn NCT01652456 Not Applicable

Search NIH Clinical Center for Cannabis Abuse

Genetic Tests for Cannabis Abuse

Anatomical Context for Cannabis Abuse

MalaCards organs/tissues related to Cannabis Abuse:

41
Testes, Lung, Brain, Eye, Thyroid, Temporal Lobe

Publications for Cannabis Abuse

Articles related to Cannabis Abuse:

(show top 50) (show all 140)
# Title Authors Year
1
Age Invariance of the Cannabis Abuse Screening Test in a Probabilistic Sample of Cannabis Users. ( 29495016 )
2018
2
Cannabinoids for the treatment of cannabis abuse disorder. ( 30339139 )
2018
3
Cannabis Abuse or Dependence During Pregnancy: A Population-Based Cohort Study on 12 Million Births. ( 30448107 )
2018
4
Synergistic effects of marijuana abuse and HIV infection on neural activation during a cognitive interference task. ( 30239074 )
2018
5
Long lasting effects of chronic heavy cannabis abuse. ( 28314070 )
2017
6
The Cannabis Abuse Screening Test and the DSM-5 in the general population: Optimal thresholds and underlying common structure using multiple factor analysis. ( 29124816 )
2017
7
Transverse myelitis associated with heroin and cannabis abuse: a new issue from the past. ( 27003705 )
2016
8
Cannabis Abuse Is Increasing and Associated with Increased Emergency Department Utilization in Gastroenterology Patients. ( 26935430 )
2016
9
Shifting the Paradigm: Adolescent Cannabis Abuse and the Need for Early Intervention. ( 26800275 )
2016
10
The Cannabis Abuse Screening Test (CAST) revisited: examining measurement invariance by age. ( 27723274 )
2016
11
Assessing the structure of the CAST (Cannabis Abuse Screening Test) in 13 European countries using multigroup analyses. ( 27981662 )
2016
12
Marijuana Abuse in Singapore. ( 27922141 )
2016
13
Acute myocardial infarction and ischemic stroke coexistence due to marijuana abuse in an adolescent. ( 27389155 )
2016
14
Small Molecule Detection in Saliva Facilitates Portable Tests of Marijuana Abuse. ( 27434697 )
2016
15
Concomitant cannabis abuse/dependence in patients treated with opioids for non-cancer pain. ( 26246069 )
2015
16
Properties of the Cannabis Abuse Screening Test (CAST) in the general population. ( 26077195 )
2015
17
Sex-dependent vulnerability to cannabis abuse in adolescence. ( 25941498 )
2015
18
Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia. ( 25716487 )
2015
19
The influence of age and gender on the likelihood of endorsing cannabis abuse/dependence criteria. ( 25481449 )
2015
20
Methamphetamine and cannabis abuse in adolescence: a quasi-experimental study on specific and long-term neurocognitive effects. ( 25636791 )
2015
21
Authors' Response to "Parental Cannabis Abuse and Accidental Intoxication in Children: Prevention by Detecting Neglectful Situations and At-Risk Families". ( 26427950 )
2015
22
Commentary on Kosty et al. (2015): Cannabis abuse from one generation to the next-a heightened vulnerability in women? ( 26094497 )
2015
23
The impacts of marijuana dispensary density and neighborhood ecology on marijuana abuse and dependence. ( 26154479 )
2015
24
Cortical thinness and volume differences associated with marijuana abuse in emerging adults. ( 26249265 )
2015
25
Cannabinoid hyperemesis should be recognised as an effect of chronic cannabis abuse. ( 25120899 )
2014
26
Long-term cannabis abuse and early-onset cannabis use increase the severity of cocaine withdrawal during detoxification and rehospitalization rates due to cocaine dependence. ( 25262527 )
2014
27
Functioning of Cannabis Abuse and Dependence Criteria Across Two Different Countries: The United States and The Netherlands. ( 25363693 )
2014
28
Cannabis abuse and age at onset in schizophrenia patients with large, rare copy number variants. ( 24685822 )
2014
29
Predicting cannabis abuse screening test (CAST) scores: a recursive partitioning analysis using survey data from Czech Republic, Italy, the Netherlands and Sweden. ( 25264894 )
2014
30
Increased CB2 mRNA and anandamide in human blood after cessation of cannabis abuse. ( 24788457 )
2014
31
Parental Cannabis Abuse and Accidental Intoxications in Children: Prevention by Detecting Neglectful Situations and At-Risk Families. ( 25407034 )
2014
32
The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. ( 24990397 )
2014
33
Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. ( 24682777 )
2014
34
Late onset epilepsy associated with marijuana abuse: a case report with MRI findings. ( 25120871 )
2014
35
Acute temporal lobe infarction in a young patient associated with marijuana abuse: An unusual cause of stroke. ( 25215152 )
2014
36
Contributions of ethnicity to differential item functioning of cannabis abuse and dependence symptoms. ( 23384380 )
2013
37
Adolescent ischemic stroke associated with anabolic steroid and cannabis abuse. ( 23382306 )
2013
38
Pathways to Psychosis in Cannabis Abuse. ( 23491968 )
2013
39
Psychometric Properties of the Cannabis Abuse Screening Test in Hungarian Samples of Adolescents and Young Adults. ( 24217457 )
2013
40
Additive effects of childhood abuse and cannabis abuse on clinical expressions of bipolar disorders. ( 24028906 )
2013
41
WITHDRAWN: Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. ( 23780682 )
2013
42
Monitoring of chronic Cannabis abuse: an LC-MS/MS method for hair analysis. ( 23305934 )
2013
43
Chronic cannabis abuse, delta-9-tetrahydrocannabinol and thyroid function. ( 22821384 )
2013
44
Cannabis abuse is associated with better emotional memory in schizophrenia: a functional magnetic resonance imaging study. ( 23906663 )
2013
45
Cannabis abuse in adolescence and the risk of psychosis: A brief review of the preclinical evidence. ( 23916409 )
2013
46
A validation of the Cannabis Abuse Screening Test (CAST) using a latent class analysis of the DSM-IV among adolescents. ( 23519957 )
2013
47
Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. ( 22907121 )
2013
48
Characteristics of perinatal women seeking treatment for marijuana abuse in a community-based clinic. ( 23737012 )
2013
49
Neurological soft signs in patients with psychosis and cannabis abuse: a systematic review and meta-analysis of paradox. ( 22716154 )
2012
50
Validation of the Cannabis Abuse Screening Test in a sample of cannabis inpatients. ( 22472963 )
2012

Variations for Cannabis Abuse

Expression for Cannabis Abuse

Search GEO for disease gene expression data for Cannabis Abuse.

Pathways for Cannabis Abuse

GO Terms for Cannabis Abuse

Cellular components related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron projection GO:0043005 9.33 CHRNB3 CNR2 SLC17A8
2 axon GO:0030424 9.13 BDNF CNR1 NGF
3 dendrite GO:0030425 8.92 BDNF CNR2 NGF SLC17A8

Biological processes related to Cannabis Abuse according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.57 BDNF NGF
2 neuron projection morphogenesis GO:0048812 9.56 BDNF NGF
3 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.55 CNR1 CNR2
4 modulation of chemical synaptic transmission GO:0050804 9.54 BDNF NGF
5 sensory perception of pain GO:0019233 9.52 CNR1 CNR2
6 response to nicotine GO:0035094 9.51 CHRNB3 CNR1
7 peripheral nervous system development GO:0007422 9.49 BDNF NGF
8 regulation of neuron differentiation GO:0045664 9.48 BDNF NGF
9 neurotrophin TRK receptor signaling pathway GO:0048011 9.46 BDNF NGF
10 nerve development GO:0021675 9.43 BDNF NGF
11 memory GO:0007613 9.43 BDNF CNR1 NGF
12 nerve growth factor signaling pathway GO:0038180 9.4 BDNF NGF
13 negative regulation of nitric-oxide synthase activity GO:0051001 9.37 CNR1 CNR2
14 positive regulation of collateral sprouting GO:0048672 9.32 BDNF NGF
15 negative regulation of mast cell activation GO:0033004 9.16 CNR1 CNR2
16 negative regulation of action potential GO:0045759 8.96 CNR1 CNR2
17 cannabinoid signaling pathway GO:0038171 8.62 CNR1 CNR2

Molecular functions related to Cannabis Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cannabinoid receptor activity GO:0004949 8.62 CNR1 CNR2

Sources for Cannabis Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....